Roche To Make Further In-Roads With Evrysdi In Newborn And Older SMA Patients

50% Of Older US Patients Untreated

Roche’s Evrysdi is set to expand its license into pre-symptomatic children this year but the company is also focused on how to get greater numbers of older patients to seek treatment.

Roche_Basel
Roche's Evrysdi is third to market in SMA, but is building up a competitive profile to challenge Spinraza and Zolgensma • Source: Alamy

Roche looks set to make further in-roads into the spinal muscular atrophy (SMA) market with Evrysdi, with new data backing up its use in pre-symptomatic babies as well as older patients.

The company has just unveiled updated interim data suggesting its oral therapy Evrysdi (risdoplam) can achieve similar results to Biogen’s...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Neurological

More from Therapeutic Category